Oncohematology in the Era of Immunotherapies: The Key Role of the Human Leukocyte Antigen (HLA) Complex
Year: 2026
Type: article
Abstract: Immunotherapy has transformed the therapeutic landscape of onco-hematology, evolving from historical allogeneic hematopoietic stem cell transplantation (HSCT) to modern chimeric antigen receptor (CAR) T/NK cell therapies, bispecific antibodies, and immune checkpoint inhibitors. Central to this immunological cross-talk is the Human Leukocyte Antigen (HLA) system, which governs self/non-self-discrimination, alloreactivity, and tumor immune evasion across both classical allografts and novel adoptive cellular platforms. Facing hematological malignancies, ranging from acute leukemias and multiple myeloma to chronic leukemias and lymphomas, clinicians must overcome tumor immune escape while managing treatment-related toxicities and Graft-versus-Host Disease (GvHD). Advances in high-throughput molecular biology techniques, notably Next-Generation Sequencing (NGS) and long-read sequencing, have become indispensable for high-resolution HLA matching, minimal residual disease (MRD) monitoring, and chimerism analysis. Furthermore, gene-editing strategies (e.g., CRISPR/Cas9) targeting TRAC, B2M, and CIITA, alongside HLA-E engineering and induced pluripotent stem cell (iPSC) technology, are driving the development of universal “off-the-shelf” effector platforms that bypass classic HLA barriers. In this review, we provide a conceptual synthesis of immunotherapeutic paradigms in onco-hematology, highlighting the pivotal role of HLA biology and molecular diagnostics in shaping next-generation personalized cellular therapies.
Source: Cells
Institutions: Aix-Marseille Université, Établissement Français du Sang, Anthropologie Bio-Culturelle, Droit, Éthique & Santé, Inserm, Hôpital de la Conception, Theories and Approaches of Genomic Complexity, Centre National de la Recherche Scientifique, Institut de Neurosciences de la Timone, Hôpital de la Timone
Language: English
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Keywords: HLA system, oncohematology, immunotherapy, hematopoietic stem cell transplantation, CAR T-cell therapy, NK cell therapy, bispecific antibodies, immune checkpoint inhibitors, tumor immune evasion, graft-versus-host disease, minimal residual disease, chimerism analysis, HLA matching, genome editing, induced pluripotent stem cells, hematologic malignancies, allogeneic transplantation
Open Access status: gold
Estimated APC paid: $3,258
OpenAlex ID: W7236822805
